This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Historx, Inc., Radiation Therapy Oncology Group of the American College of Radiology. Active years: 2013.
Company Filing History:
1 out of 17 
1 out of 1 Years Active: 2013
Title: Agnes Ang: Innovator in Molecular Markers and Clinical Outcomes
Introduction
Agnes Ang is a notable inventor based in Newbury Park, CA (US). She has made significant contributions to the field of molecular markers and their correlation with clinical outcomes in patients with glioblastoma multiforme (GBM). Her work has implications for treatment strategies and patient prognosis.
Latest Patents
Agnes Ang holds a patent titled "Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib." This patent highlights the differences in significant biomarkers for Gefitinib-treated GBM patients compared to historical, radiation-treated, and non-Gefitinib-treated patients. The findings indicate that in Gefitinib-treated patients, higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR correlate with significantly worse clinical outcomes. Conversely, in non-Gefitinib-treated patients, those with PTEN-deficiency and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB, and lower levels of nuclear Survivin exhibited adverse clinical outcomes, emphasizing the treatment-dependency of these biomarkers.
Career Highlights
Throughout her career, Agnes Ang has worked with prominent organizations such as Historx, Inc. and the Radiation Therapy Oncology Group of the American College of Radiology. Her expertise in molecular biology and clinical research has positioned her as a key figure in advancing the understanding of GBM treatment outcomes.
Collaborations
Agnes has collaborated with esteemed colleagues, including Arnab Chakravarti and Robert Pinard. These partnerships have further enriched her research and contributed to the development of innovative solutions in the field.
Conclusion
Agnes Ang's work in the correlation of molecular markers with clinical outcomes represents a significant advancement in the treatment of GBM. Her contributions continue to influence the landscape of cancer research and patient care.